Octreotide – A Review of its Use in Treating Neuroendocrine Tumours

Costa, Frederico; Gumz, Brenda Pires

doi:10.17925/ee.2014.10.01.70

Cited by 13 publications

(11 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The synthetic SST analogue octreotide (Sandostatin ® , Figure 9b) is highly effective in inhibiting hormone secretion and is used for the treatment of various endocrine and malignant disorders including NETs, acromegaly and gastroenteropancreatic tumors [209,210,211]. Moreover, it shows inhibitory activity against breast cancer growth in nude mice and in cultured cells either alone or in combination with other drugs [212,213].…”

Section: Gpcrs In Breast Cancer: Signaling Biology and Modulatorsmentioning

confidence: 99%

GPCR Modulation in Breast Cancer

Lappano

Jacquot

Maggiolini

2018

IJMS

View full text Add to dashboard Cite

Breast cancer is the most prevalent cancer found in women living in developed countries. Endocrine therapy is the mainstay of treatment for hormone-responsive breast tumors (about 70% of all breast cancers) and implies the use of selective estrogen receptor modulators and aromatase inhibitors. In contrast, triple-negative breast cancer (TNBC), a highly heterogeneous disease that may account for up to 24% of all newly diagnosed cases, is hormone-independent and characterized by a poor prognosis. As drug resistance is common in all breast cancer subtypes despite the different treatment modalities, novel therapies targeting signaling transduction pathways involved in the processes of breast carcinogenesis, tumor promotion and metastasis have been subject to accurate consideration. G protein-coupled receptors (GPCRs) are the largest family of cell-surface receptors involved in the development and progression of many tumors including breast cancer. Here we discuss data regarding GPCR-mediated signaling, pharmacological properties and biological outputs toward breast cancer tumorigenesis and metastasis. Furthermore, we address several drugs that have shown an unexpected opportunity to interfere with GPCR-based breast tumorigenic signals.

show abstract

Section: Gpcrs In Breast Cancer: Signaling Biology and Modulatorsmentioning

confidence: 99%

GPCR Modulation in Breast Cancer

Lappano

Jacquot

Maggiolini

2018

IJMS

View full text Add to dashboard Cite

show abstract

“…This may reflect the unique tumor biology of NET [7][8][9][10][11][16][17][18][19][20][21]. Furthermore, most studies on the antineoplastic effects of octreotide LAR included populations with different primary sites, and it was difficult to compare the results of PFS and OS between our study and other reports [7][8][9][17][18][19][20][21][22]; only a few retrospective studies and two small prospective studies in patients with gastrinoma had selected population of patients with pan-NET, who initially were treated using octreotide LAR [7,8,17,20,23]. Most authors agree that ORR of GEP-NET exposed to octreotide LAR is very low (approximately 5%).…”

Section: Progression-free Survivalmentioning

confidence: 81%

Evaluation of survival outcomes in patients with sporadic, advanced, unresectable well-differentiated pancreatic neuroendocrine tumors treated initially with octreotide LAR and subsequent therapeutical approaches on relapse. A real-world data set

Kolasińska-Ćwikła

Gutowska²,

Osowiecka³

et al. 2022

Oncol Clin Pract

View full text Add to dashboard Cite

Introduction. Somatostatin analogs (SSA) are widely used in the treatment of patients with well-differentiated neuroendocrine tumors (NET). There are limited reports about the role of octreotide LAR in first-line therapy of advanced pancreatic NET (pan-NET). This study aimed to evaluate the antiproliferative effect of octreotide LAR in patients with sporadic, advanced, unresectable pan-NET, based on progression-free survival (PFS).Material and methods. This was a retrospective analysis of 374 patients with pan-NET; 41 treated subjects were included. The primary endpoint was PFS defined as the time to disease progression (Response Evaluation Criteria in Solid Tumors: RECIST). Univariate and multivariate analyses were used to identify predictors of PFS. Secondary endpoints included overall survival (OS) and second-line therapies after progression.Results. There were 13 (32%) patients with G1 pan-NET and 28 (68%) with pan-NET G2, 21 female and 20 male, with mean age 55.4 (range 29-87). Median PFS was 9.0 months (95% CI 4.7-24.0). Subgroup analysis revealed that G1 and no-bulky liver disease (< 25% liver volume) were associated with significantly longer PFS. Univariate analysis confirmed a correlation between G1 [0.34 hazard rate (HR) of progression or death (95% CI 0.16-0.72)] and no-bulky liver disease HR = 0.31 (95% CI 0.13-0.71). Multivariable analysis demonstrated that only functional (secretory) pan-NET was associated as an independent factor with shorter PFS HR = 2.97 (95% CI 1.0-8.74).Median OS was 105.4 months (95% CI 40.0-172.0). After relapse following initial systemic therapy, the second line was used in 34 subjects, 3rd line in 18th, and 4th line in 9 subjects. Conclusions.Octreotide LAR shows moderate antiproliferative activity in pan-NET. Prolonged PFS may be associated with G1 and low-volume metastatic liver disease. In patients with progressive disease, various treatment options were used, which resulted in median OS of 105.4 months.

show abstract

“…Zudem konnte für dieses Präparat in der PROMID-Studie bei Patienten mit NETs des Dünndarms eine signifikant längere progressfreie Überlebenszeit im Vergleich zum Placeboarm gezeigt werden (14,3 vs. 6 Monate, HR 0,34, p < 0,0001) 6 7 . Für Patienten mit NETs des Pankreas gibt es zu Octreotid bisher nur retrospektive Studien 8 . Die aktuelle AWMF-Leitlinie empfiehlt eine Behandlung mit SSAs bei Patienten mit metastasierten/nicht resektablen somatostatinrezeptorpositiven NET, wenn die Proliferationsrate (Ki67) < 10 % liegt, wie bei der hier vorgestellten Patientin 9 .…”

Section: Diskussionunclassified

Ungewöhnliche Ursache einer Hyperkalzämie in der Schwangerschaft

Mehl

Schrader

Winterberg

et al. 2022

TumorDiagnostik & Therapie

View full text Add to dashboard Cite

Zusammenfassung Hintergrund In der Schwangerschaft diagnostizierte neuroendokrine Tumoren (NET) sind eine absolute Rarität. Die vorliegende Kasuistik beschreibt Diagnostik und Therapie eines im 2. Trimenon symptomatisch gewordenen metastasierten NET des Pankreas. Fallbeschreibung Eine 33-jährige Patientin stellte sich in der 19. Schwangerschaftswoche (SSW) mit persistierender Diarrhoe in der Notaufnahme vor. Laborchemisch fiel eine ausgeprägte Hyperkalzämie (3,53 mmol/l) auf. In der Bildgebung fand sich eine Raumforderung im Bereich des Pankreaskorpus/-schwanzes mit ausgedehnter Lebermetastasierung. Histologisch zeigte sich ein NET (G2, SSTR-positiv) mit einer paraneoplastischen Parathormon-related-Peptide-Sekretion als Ursache der Hyperkalzämie. Unter einer Therapie mit Octreotid normalisierte sich das Kalzium, die Diarrhoe sistierte. Nach Geburt eines gesunden Kindes (32. SSW per sectio) fand sich ein Progress; der Pankreastumor wurde komplett entfernt, die Leberfiliae so weit wie möglich. In einem postoperativen CT zeigten sich verbliebene metastasensuspekte Läsionen, eine palliative Therapie mit Lanreotid wurde eingeleitet. Darunter ist die Patientin seit einem Jahr symptomfrei, das Serumkalzium blieb normwertig. Das Kind entwickelte sich unauffällig. Diskussion Dieser ungewöhnliche Fall zeigt, dass es auch bei ausgedehnt metastasierten symptomatischen NETs in der Schwangerschaft weitreichende diagnostische und therapeutische Optionen geben kann, die in enger interdisziplinärer Zusammenarbeit unter sorgfältiger Risiko-Nutzen-Abwägung für Mutter und Kind eine Fortführung der Schwangerschaft erlauben.

show abstract

Octreotide – A Review of its Use in Treating Neuroendocrine Tumours

Cited by 13 publications

References 40 publications

GPCR Modulation in Breast Cancer

GPCR Modulation in Breast Cancer

Evaluation of survival outcomes in patients with sporadic, advanced, unresectable well-differentiated pancreatic neuroendocrine tumors treated initially with octreotide LAR and subsequent therapeutical approaches on relapse. A real-world data set

Ungewöhnliche Ursache einer Hyperkalzämie in der Schwangerschaft

Contact Info

Product

Resources

About